Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump lashes out at Crockett, renews call for...
Trump goes after Zelenskyy over ‘land swapping’ dispute,...
Democratic whistleblower told FBI that Adam Schiff approved...
MORNING GLORY: Trump meets Putin amid an era...
‘Things need to change’: Senate Democrats sharpen criticism...
Mamdani zings Cuomo in rent-stabilized housing spat during...
Unearthed emails reveal White House nixed Biden visiting...
Strong drilling targets identified next to high-grade gold-copper...
Seymour Lithium Project Achieves Permitting Milestone
Acquisition of Silver Extraction Technology
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

previous post
HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States
next post
Stop funding the woke and the stupid

You may also like

Left-wing movie director Oliver Stone rips Democrats’ ‘lying’...

April 7, 2025

Hamas releases 3 more hostages, including US citizen,...

February 1, 2025

Israeli ministers frustrated over US, IDF leak on...

October 1, 2024

White House responds to ‘Rocket Man’ and North...

July 31, 2025

Cotton calls on IRS to pull Muslim advocacy...

August 6, 2025

Trump calls for next presidential debate to be...

July 22, 2024

Axed government watchdog says Trump has right to...

March 8, 2025

Trump says ‘I don’t care when you vote’...

October 15, 2024

Arkansas Gov Sarah Sanders will not join the...

November 13, 2024

Biden bites babies visiting for White House Halloween...

October 31, 2024

Recent Posts

  • Trump lashes out at Crockett, renews call for cognitive test
  • Trump goes after Zelenskyy over ‘land swapping’ dispute, lays out ‘feel out meeting’ with Putin
  • Democratic whistleblower told FBI that Adam Schiff approved classified leaks to target Trump
  • MORNING GLORY: Trump meets Putin amid an era done away with John Quincy Adams’ ‘abroad’
  • ‘Things need to change’: Senate Democrats sharpen criticism of Israel as humanitarian concerns grow

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (867)
    • Investing (2,729)
    • Politics (3,369)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.